Last reviewed · How we verify

Ramelteon Pill

Virginia Commonwealth University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Ramelteon Pill is a Small molecule drug developed by Virginia Commonwealth University. It is currently FDA-approved. Also known as: Ramelteon.

Ramelteon is a small molecule that acts as a melatonin receptor agonist. It has been studied for various conditions, including insomnia, cirrhosis, and bipolar disorder, among others.

At a glance

Generic nameRamelteon Pill
Also known asRamelteon
SponsorVirginia Commonwealth University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ramelteon Pill

What is Ramelteon Pill?

Ramelteon Pill is a Small molecule drug developed by Virginia Commonwealth University.

Who makes Ramelteon Pill?

Ramelteon Pill is developed and marketed by Virginia Commonwealth University (see full Virginia Commonwealth University pipeline at /company/virginia-commonwealth-university).

Is Ramelteon Pill also known as anything else?

Ramelteon Pill is also known as Ramelteon.

What development phase is Ramelteon Pill in?

Ramelteon Pill is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing